Last reviewed · How we verify
Corvert (IBUTILIDE)
Ibutilide (Corvert), marketed by Pfizer, is a potassium channel blocker indicated for the rapid conversion of atrial fibrillation or atrial flutter, with a key composition patent expiring in 2028. Its primary competitive advantage lies in its specific mechanism of action and FDA approval for rapid conversion, distinguishing it from older off-patent alternatives like amiodarone and bretylium. The primary risk is the increasing competition from generic dofetilide and the upcoming patent expiry of dronedarone in 2031, which may erode market share.
At a glance
| Generic name | IBUTILIDE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Antiarrhythmic |
| Target | Potassium voltage-gated channel subfamily H member 2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1995 |
Approved indications
- Rapid conversion of atrial fibrillation or atrial flutter
Common side effects
- Ventricular extrasystoles
- Nonsustained monomorphic VT
- Nonsustained polymorphic VT
- Hypotension
- Bundle branch block
- AV block
- Bradycardia
- Tachycardia
- Hypertension
- QT segment prolonged
- Palpitation
- Nausea
Drug interactions
- Digoxin
- Calcium channel blocking agents
- Beta-adrenergic blocking agents
Key clinical trials
- Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (PHASE4)
- Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (PHASE4)
- ECGI in Patients With Persistent Atrial Fibrillation
- ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization (NA)
- Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes (PHASE4)
- Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation (NA)
- Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening (PHASE2)
- Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corvert CI brief — competitive landscape report
- Corvert updates RSS · CI watch RSS
- Pfizer portfolio CI